PS516 Unit 3 Antidepressant Case Paper Example

Six Weeks on Sertraline: A PS516 Unit 3 Paper Weighing Antidepressant Evidence and Side Effects for a Packing-House Supervisor

[Student Name]

Purdue University Global

PS516: Psychopharmacology

Unit 3 Antidepressant Case Paper

[Instructor Name]

[Date]

The client, her family, the clinic and every detail of the case are composite and illustrative; the sources cited are real.

The Client and the Question

Lupe, 54, runs a crew of apple sorters and started 50 milligrams of sertraline a day in October, prescribed by our clinic's psychiatric nurse practitioner for moderate major depression that followed her husband's stroke. At six weeks her PHQ-9 score has dropped from 17 to 12, she sleeps six hours most nights instead of four, and she has started going to her grandchildren's games again. She also reports mild nausea in the mornings, less interest in sex and a feeling that the medicine "makes me flat." She asked me whether she should stop.

My role is not to answer that question for her. It is to understand the evidence well enough to help her think it through, to report accurately to the prescriber and to make sure the decision is made with her, not around her.

How SSRIs Work

Sertraline is a selective serotonin reuptake inhibitor. Stahl (2021) explains that SSRIs block the serotonin transporter, the protein that pulls serotonin back into the nerve cell after release, so more serotonin remains active at the synapse. The transporter is blocked by the first evening; the lift in mood, when it comes, takes several weeks. The delay suggests the benefit comes from slower changes that follow, such as adjustments in receptors and in how brain circuits adapt, rather than from the immediate rise in serotonin itself. Side effects such as nausea often appear early because serotonin receptors in the gut respond at once.

What the Evidence Shows

Cipriani et al. (2018) pooled 522 trials of 21 antidepressants, which together enrolled well over a hundred thousand depressed adults, and ranked the drugs against one another and against placebo. All 21 drugs were more effective than placebo over the acute phase of treatment, usually eight weeks. They were not equal, though, either in how much they helped or in how many patients quit them early for any reason. Sertraline was among the drugs that combined reasonable efficacy with good acceptability. The authors noted that the average benefit over placebo was modest and that most trials were short.

Kirsch et al. (2008) went back to the trial results that drug makers had filed with federal regulators covering four newer antidepressants; the more depressed people were when a trial began, the wider the gap between pill and placebo. For people with less severe depression the difference was small, and it reached a level usually considered clinically meaningful only in the most severe groups. The authors argued that this pattern reflected a weaker placebo response in severe depression rather than a stronger drug effect.

Read side by side, the two studies fit together: antidepressants work better than placebo, and how much better depends partly on how depressed a person is when treatment begins.

Applying the Evidence to Lupe

Lupe started at moderate severity and has improved by five points on the PHQ-9. Some of that improvement may reflect the natural course of grief, time and support; some may reflect the medication. The evidence from Cipriani and colleagues suggests sertraline was a reasonable first choice, and Lupe's improvement in sleep and activity is real progress. Her score of 12 also shows she has not reached remission.

Her side effects matter as much as the efficacy data. Nausea from SSRIs often fades in the first weeks, but sexual side effects and emotional blunting can persist, and they are common reasons people stop antidepressants on their own. Quitting sertraline overnight can bring its own week of trouble, often light-headedness, a short temper and an achy, flu-ish feeling, so any stop should be planned with the prescriber.

What I Brought to the Prescriber

With Lupe's agreement, I sent our nurse practitioner a consult note before her next visit. It listed her PHQ-9 scores at baseline and six weeks, her improvement in sleep and activity, the three side effects in her words, her question about stopping and her worry that "flat" might mean the grief is just being covered up. I also noted that she had no thoughts of self-harm and was taking every dose.

The nurse practitioner discussed three options with Lupe: continue the current dose and reassess in four weeks, since benefits and side effects often shift over that time; adjust the dose; or switch to a different antidepressant with a different side effect profile. The decision would be Lupe's, informed by the prescriber.

The Counseling Side

Medication is only part of Lupe's care. Her depression began with a major loss and a new role as her husband's caregiver. Our care plan includes weekly sessions using behavioral activation, scheduling the activities she has stopped, and connecting her with a stroke caregiver group at the hospital. Some of the "flat" feeling may be grief that has not yet been expressed, and that belongs in counseling, not only in a dose decision. Lupe has not cried about her husband's stroke in front of anyone, she told me, because she is the one holding the family together.

Watching for Risk

Antidepressants carry a warning about suicidal thinking in young people, and while Lupe is 54, any worsening of mood, new agitation or thoughts of self-harm during the first months of treatment or after a dose change must be reported at once. At each visit I ask Lupe directly about thoughts of death or suicide and record her answers. I also check whether she is taking any other medicines that affect serotonin, such as tramadol for her back or an over-the-counter cough syrup, since combinations raise the risk of serotonin toxicity. So far she takes only sertraline and an occasional antacid, and she knows to tell me or the pharmacist before adding anything.

Limits

Trial averages do not predict how one person will respond. Most of the trials Cipriani and colleagues analyzed lasted eight weeks, and Kirsch and colleagues looked at only four drugs. Neither tells us how Lupe will do over a year.

Conclusion

Lupe's case shows how a care manager uses psychopharmacology without prescribing. Stahl explains why sertraline takes weeks to help and causes early side effects, Cipriani and colleagues show it is a reasonable choice among antidepressants, and Kirsch and colleagues explain why the benefit over placebo varies with severity. My job was to bring her progress, side effects and questions to the prescriber accurately and to keep counseling for grief and caregiving going alongside the medication.

References

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7

Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), Article e45. https://doi.org/10.1371/journal.pmed.0050045

Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.